List of Centivax patents | 7 results

Name	Description	Patent Applicant	Current Assignee	Patent Jurisdiction	Patent Number	Date of Patent
‌ US Patent 11560409 Epitope focusing by variable effective antigen surface concentration	Patent 11560409 was granted and assigned to Centivax on January, 2023 by the United States Patent and Trademark Office.	Centivax	Centivax	United States Patent and Trademark Office	11560409	January 24, 2023
‌ US Patent 11028167 Anti-SARS-Cov-2 antibodies derived from 3bgf	Patent 11028167 was granted and assigned to Centivax on June, 2021 by the United States Patent and Trademark Office.	Centivax	Centivax	United States Patent and Trademark Office	11028167	June 8, 2021
‌ US Patent 11053304 Anti-SARS-Cov-2 antibodies derived from 6nb6	Patent 11053304 was granted and assigned to Centivax on July, 2021 by the United States Patent and Trademark Office.	Centivax	Centivax	United States Patent and Trademark Office	11053304	July 6, 2021
‌ US Patent 11028150 Anti-SARS-CoV-2 antibodies derived from 2DD8	Patent 11028150 was granted and assigned to Centivax on June, 2021 by the United States Patent and Trademark Office.	Centivax	Centivax	United States Patent and Trademark Office	11028150	June 8, 2021
‌ US Patent 11021532 Superhuman anti-SARS-CoV-2 antibodies and uses thereof	Patent 11021532 was granted and assigned to Centivax on June, 2021 by the United States Patent and Trademark Office.	Centivax	Centivax	United States Patent and Trademark Office	11021532	June 1, 2021
‌ US Patent 11021531 Anti-SARS-Cov-2 antibodies derived from 2GHW	Patent 11021531 was granted and assigned to Centivax on June, 2021 by the United States Patent and Trademark Office.	Centivax	Centivax	United States Patent and Trademark Office	11021531	June 1, 2021
‌ US Patent 11034762 Anti-SARS-Cov-2 antibodies derived from CR3022	Patent 11034762 was granted and assigned to Centivax on June, 2021 by the United States Patent and Trademark Office.	Centivax	Centivax	United States Patent and Trademark Office	11034762	June 15, 2021